D'Onofrio Matthew J 4
4 · Evoke Pharma Inc · Filed Mar 3, 2020
Insider Transaction Report
Form 4
Evoke Pharma IncEVOK
D'Onofrio Matthew J
Exec VP, Chief Bus. Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-02-28+200,000→ 200,000 totalExercise: $1.23Exp: 2030-02-27→ Common Stock (200,000 underlying) - Award
Common Stock
2020-03-02$0.85/sh+25,000$21,250→ 263,759 total
Footnotes (2)
- [F1]These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c) and Rule 16b-3(d).
- [F2]One-half of the stock options will vest in 48 equal monthly installments over the four-year period beginning on January 1, 2020, subject to the reporting person's continued service to the issuer through each such vesting date. The other one-half of the stock options will vest in 48 equal monthly installments over the four-year period beginning on the date, if any, on which the U.S. Food and Drug Administration approves the Issuer's new drug application for Gimoti, subject to the reporting person's continued service to the issuer through each such vesting date.